All In Biotech

Drug Trial Radar · NCT06334432

Safety and Efficacy Study of NUV-1511 in Adult Patients With Advanced Solid Tumors

A Phase 1/2, First-in-Human, Safety and Efficacy Study of NUV-1511 in Adult Patients With Advanced Solid Tumors

Last checked: Nov 20, 2026Latest source record: Jan 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

466

Planned (sponsor's estimate)

Start

Mar 14, 2024

Primary completion

Mar 2027

Study completion Oct 2027

Sponsor

Lead sponsor
Nuvation Bio Inc.Industry
Sponsor type
Industry
First posted
Mar 28, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

NUV-1511-01 is a first-in human, open- label, Phase 1/2 to evaluate the safety and efficacy of NUV-1511 in patients with advanced solid tumors. The Phase 1 portion include patients with advanced solid tumors and is designed to determine the safety and the tolerability of doses of NUV-1511. In Phase 2, NUV-1511 will be given to determine the efficacy of patients with advanced solid tumors.

Conditions

  • Advanced Solid Tumor
  • HER2-negative Breast Cancer
  • Metastatic Castration-resistant Prostate Cancer (mCRPC)
  • Pancreatic Cancer
  • Platinum-resistant Ovarian Cancer (PROC)

Interventions

  • NUV-1511Drug

    Novel small molecule

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase 1: Assess safety and tolerability of NUV-1511 in advanced solid tumorsTime frame: First 28 days of dosing (DLT evaluation period)
  2. Phase 1: Identify recommended dosing schedule(s) and corresponding Phase 2 dose(s) (RP2D(s))Time frame: First 28 days of dosing (DLT evaluation period)
  3. Phase 2: Evaluate the efficacy of NUV-1511 in advanced solid tumors and selected tumor type(s)Time frame: From date of enrollment to date of disease progression, withdrawal of consent, or initiation of subsequent anticancer treatment or up to a period of 5 years, whichever occurs first
  4. Phase 2: Confirm the optimal NUV-1511 dose level/schedule for further developmentTime frame: Periodic efficacy assessments from date of enrollment to date of disease progression, withdrawal of consent, or initiation of subsequent anticancer treatment or up to a period of 5 years, whichever occurs first
  5. Phase 2: Confirm the optimal NUV-1511 target tumor types for further developmentTime frame: Periodic efficacy assessments from date of enrollment to date of disease progression, withdrawal of consent, or initiation of subsequent anticancer treatment or up to a period of 5 years, whichever occurs first

Locations

8 sites in 1 country. Site status is shown where the registry gives one.

  • Karmanos Cancer Center

    Detroit, Michigan

  • Hackensack University Medical Center

    Hackensack, New Jersey

  • Memorial Sloan-Kettering Cancer Center

    New York, New York

  • Carolina BioOncology Institute

    Huntersville, North Carolina

  • NEXT Oncology

    Irving, Texas

  • START Mountain

    Salt Lake City, Utah

  • NEXT Oncology

    Fairfax, Virginia

  • Fred Hutchinson

    Seattle, Washington

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.